Review Article
Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis
Table 1
Characteristics of included studies.
| Studies | Samples | Median age (years) |
Intervention regimens |
Control regimens |
Design | Phase |
Median OS (months) | Median nPFS (months) | W-T | W | W-T | W |
|
Zhuang et al., 2013 [21] | 23 | 31 | 60 (37–76) | 63 (43–81) | WBRT 30 Gy/10 f plus erlotinib 150 mg/day | WBRT 30 Gy/10 f | Case-control | II | NR | NR |
|
Lee et al., 2014 [22] | 40 | 40 | 61.3 (48–75) | 62.2 (41–73) | WBRT 20 Gy/5 f plus erlotinib 100 mg/day | WBRT 20 Gy/5 f + placebo | Randomized | II | 3.4/2.9 | 1.6/1.6 |
|
Fu et al., 2012 [23] | 38 | 123 | A56 (38–77) | WBRT 30–40 Gy/2-3 W plus gefitinib 250 mg/day | WBRT 30–40 Gy/2-3 W | Case-control | NR | NR | NR |
|
Wu et al., 2012 [24] | 35 | 18 | 18–65 | WBRT 40 Gy/20 f plus gefitinib 250 mg/day | WBRT 40 Gy/20 f | Randomized | NR | 12.1/9.8 | NR |
|
Zhou et al., 2013 [25] | 36 | 22 | 27–75 | WBRT 40 Gy/20 f or 30 Gy/10 f plus gefitinib 250 mg/day or erlotinib 100 mg/day | WBRT 40 Gy/20 f or 30 Gy/10 f plus Taxol 135–175 mg/m2 d1 or Alimta 500 mg/m2 d1 or DDP 25 mg/m2 (d1–3) | Case-control | NR | 23.2/7.1 | NR |
|
Pesce et al., 2012 [26] | 16 | 43 | 57 (46–82) | 63 (45–79) | WBRT 30 Gy/10 f plus gefitinib 250 mg/day | WBRT 30 Gy/10 f plus TMZ 75 mg/m2/day | Randomized | II | 6.3/4.9 | NR |
|
Cai et al., 2013 [27] | 65 | 92 | 66 (35–81) | WBRT 29.37~41.24 Gy, 3 Gy/d, 5 times/week plus gefitinib 250 mg/day or erlotinib 100 mg/day | WBRT 29.37~41.24 Gy, 3 Gy/d, 5 times/week | Case-control | NR | 10.6/7.7 | 6/3.4 |
|
|
Notes. W-T: WBRT plus erlotinib/gefitinib; W: WBRT; NR: not reported; OS: overall survival; PFS: progression-free survival.
|